Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a pivotal Phase 3 clinical study titled ‘A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD.’ The study aims to assess the efficacy and safety of RGX-314, a novel gene therapy for neovascular age-related macular degeneration (wet AMD), which is a leading cause of vision loss. The significance of this study lies in its potential to offer a one-time treatment alternative to current therapies that require frequent injections.
The intervention being tested is RGX-314, a genetic therapy delivered via subretinal injection, intended to provide a long-term solution for wet AMD by reducing the need for repeated treatments. The control arm of the study uses Aflibercept, a standard treatment administered every eight weeks.
The study design is interventional, randomized, and follows a parallel model with two treatment arms for RGX-314 and one control arm. It employs a quadruple masking approach to ensure unbiased results, with the primary purpose being treatment evaluation.
The study began on January 28, 2022, with an estimated completion date set for August 11, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting the potential market release of RGX-314.
The update on this study could positively influence AbbVie’s stock performance, as successful results may lead to a breakthrough in wet AMD treatment, enhancing investor confidence. Competitors in the gene therapy and ophthalmology sectors will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.